Department of Anesthesiology, University of Kansas Medical Center, Kansas City, KS 66160, USA.
J Clin Anesth. 2009 Sep;21(6):444-53. doi: 10.1016/j.jclinane.2009.05.002.
Sugammadex is a novel cyclodextrin, the first in a new class of selective binding reversal agents that terminates neuromuscular block (NMB) with the steroidal nondepolarizing agents, rocuronium and vecuronium. Sugammadex can reverse a moderate or deep NMB. The dose required depends on the level of NMB that needs to be reversed. Smaller doses are sufficient for a moderate versus deep NMB. In October 2007, a new drug application for sugammadex was submitted to the U.S. Food and Drug Administration (FDA). The FDA issued a not-approvable letter in July 2008. The manufacturer continues clinical trials.
舒更葡糖钠是一种新型的环糊精，是首个具有全新作用机制的选择性结合拮抗剂，能逆转罗库溴铵和维库溴铵所致的神经肌肉阻滞（NMB）。舒更葡糖钠能逆转中或深的 NMB。所需剂量取决于需要逆转的 NMB 程度。逆转中或深 NMB 所需的剂量较小。2007 年 10 月，舒更葡糖钠的新药申请已提交给美国食品和药物管理局（FDA）。2008 年 7 月，FDA 发出了不批准信。生产商继续进行临床试验。
